Dexcom (DXCM) Receives a Hold from BTIG
BTIG analyst Marie Thibault maintained a Hold rating on Dexcom (DXCM) today. The company’s shares closed last Monday at $418.00, close to its 52-week high of $456.23.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 30.4% and a 54.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.
Currently, the analyst consensus on Dexcom is a Moderate Buy with an average price target of $464.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $456.23 and a one-year low of $147.52. Currently, Dexcom has an average volume of 769.8K.
Based on the recent corporate insider activity of 145 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DXCM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.